Table 6.
Sensitivity and 95% CIs of diagnostic techniques and resistance detection in the groups stratified by the biopsy collection site.
| Biopsy Collection Site |
||||
|---|---|---|---|---|
| Test | Earlobe (n = 23) | Lesion (n = 33) | p-value | Adjusted p-Value⁎⁎ |
| PCR RLEP | ||||
| PureLink Kit | 12 (52.17%) (32,96-70,76) |
22 (66.67%) (49.61-80.25) |
0.415 | 0.491 |
| Nucleospin TXS | 10 (43.48%) (25.63-63.19) |
21 (63.64%) (46.62-77.81) |
0.223 | 0.269 |
| Complementary sensitivity* | ||||
| folP1 | 10 (43.48%) (25.36-63.19) |
17 (51.52%) (35.22–67.50) |
0.749 | 0.942 |
| rpoB | 9 (39.13%) (22.16-59.21) |
17 (51.52%) (35.22-67.50) |
0.521 | 0.795 |
| gyrA | 7 (30.43%) (15.60-50.87) |
14 (42.42%) (27.24-59.19) |
0.528 | 0.879 |
⁎
For the sensitivity calculation, we considered a result positive if either of the extraction kits resulted in the amplification of the target gene sequence.
⁎⁎
p-values were adjusted for BIs using a logistic regression model.
PureLink, PureLink Genomic DNA Mini Kit (Invitrogen, Thermo Fisher Scientific, Waltham, Massachusetts, USA); Nucleospin TXS, NucleoSpin Tissue XS (Macherey-Nagel, GmbH & Co. KG, Düren, Germany); folP1, dapsone resistance-associated target; rpoB, rifampicin resistance-associated target; gyrA, quinolone resistance-associated target.